The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.
The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback